Form 4: Vaxart Director Michael J. Finney Reports Significant Equity Grant and Stock Option Award

Vaxart, Inc. Director Michael J. Finney has reported the acquisition of 16,000 common shares and 95,400 stock options as part of an equity compensation grant, with vesting scheduled for mid-2026.

Summary

• Michael J. Finney, a Director of Vaxart, Inc. (VXRT), reported transactions on June 13, 2025.
• He acquired 16,000 shares of common stock at a price of $0, representing a grant upon vesting of restricted stock units.
• He also acquired 95,400 stock options with an exercise price of $0.70 per share.
• Following these transactions, Mr. Finney beneficially owns 702,840 shares of common stock and 95,400 stock options.
• Both the granted shares and stock options are scheduled to vest on the earlier of the date immediately prior to the 2026 annual meeting of stockholders or June 13, 2026.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it reflects standard director compensation, aligning interests with shareholders. It's not a major positive or negative event for the company's operations or financial health, but rather a routine governance and compensation disclosure.

Positives

• The grant of 16,000 common shares and 95,400 stock options aligns the director's interests with long-term shareholder value.
• Equity compensation is a standard practice for retaining and incentivizing key personnel.

Negatives

• The issuance of new shares and options could lead to minor dilution for existing shareholders, although the amount is relatively small in the context of total outstanding shares.

Future Outlook

The document indicates future vesting events for the granted equity, specifically on the earlier of the date immediately prior to the 2026 annual meeting of stockholders or June 13, 2026.

Industry Context

This Form 4 filing reflects a standard practice of equity-based compensation for directors in the biotechnology or pharmaceutical industry, aiming to align leadership incentives with long-term company performance and shareholder value.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options for director compensation is a common practice across the biotechnology and broader public company landscape, comparable to compensation structures at companies like Moderna (MRNA) or BioNTech (BNTX) for their non-employee directors, though specific grant sizes vary based on company size, stage, and individual contribution.
• The vesting schedule, tied to an annual meeting or a specific anniversary date, is typical for director equity awards, ensuring continued engagement and alignment over a defined period.

Corporate Governance

Related Party Transactions

• The grant of equity compensation to Michael J. Finney, a Director of Vaxart, Inc., constitutes a transaction between the company and a related party. This is a standard compensation arrangement.

Stakeholder Impact

• Shareholders: Minor potential dilution from the issuance of new shares and options, but also improved alignment of director incentives with long-term shareholder value.

Next Steps

• Vesting of 16,000 common shares on the earlier of the date immediately prior to the 2026 annual meeting of stockholders or June 13, 2026.
• Vesting of 95,400 stock options on the earlier of the date immediately prior to the 2026 annual meeting of stockholders or June 13, 2026.
• Potential exercise of 95,400 stock options by June 13, 2035.

Key Dates

Keywords

Vaxart, VXRT, SEC Form 4, Insider Trading, Director Compensation, Equity Grant, Stock Options, Restricted Stock Units, Executive Compensation, Beneficial Ownership